의학적 응용을 위한 자성 나노입자의 제조와 특성 : Preparation and Characterization of Magnetic Nanoparticles for Medical Application
저자
발행사항
전북 : 전북대학교 대학원, 2006
학위논문사항
Thesis(doctoral)-- 전북대학교 대학원 : 유기신물질공학과 2006. 8
발행연도
2006
작성언어
영어
주제어
KDC
578 판사항(4)
발행국(도시)
대한민국
형태사항
158 p.; 26 cm.
일반주기명
Preparation and Characterization of Magnetic Nanoparticles for Medical Application
지도교수 :강길선
소장기관
Chapter 1
General overview
Magnetic nanoparticles have been proposed for use as biomedical purposes to a large extent for several years. In recent years, nanotechnology has developed to a stage that makes it possible to produce, characterize and specifically tailor the functional properties of nanoparticles for clinical applications. This has led to various opportunities such as improving the quality of magnetic resonance imaging, hyperthermic treatment for malignant cells, site-specific drug delivery and the manipulation of cell membranes. To this end a variety of iron oxide particles have been synthesized. A common failure in targeted systems is due to the opsonization of the particles on entry into the bloodstream, rendering the particles recognizable by the body's major defence system, the reticulo-endothelial system. This chapter discusses each of the above bio-applications of such magnetic nanoparticles and details some of the main recent advances in biological research.
Chapter 2
Preparation and magnetic resonance imaging (MRI) effect of polyvinylpyrrolidone (PVP)-coated iron oxide nanoparticles
Polyvinylpyrrolidone (PVP)-coated iron oxide nanoparticles were prepared by the thermal decomposition of Fe(CO)5 (iron pentacarbonyl) in one step. X-ray diffraction (XRD), transmittance electron microscopy (TEM), electrophoretic light scattering (ELS), infrared spectroscopy (FTIR) and X-ray photoelectron spectroscopy (XPS) were used to characterize the PVP-coated iron oxide nanoparticles with the variation of the molar ratio of PVP/Fe(CO)5, solvent and molecular weight of PVP. 50-100 nm sized iron oxide nanoclusters with spherical shape were formed in dimethylformamide (DMF) used as a solvent and exhibited an enhanced stability in the aqueous media. Their magnetic properties were investigated by superconducting quantum interface device (SQUID). The in vitro cytotoxicity test revealed that the polyvinylpyrrolidone-coated iron oxide nanoparticles exhibited excellent biocompatibility by MTT assay. Magnetic resonance imaging (MRI) effect was observed with the administration of polyvinylpyrrolidone-coated iron oxide nanoparticles through the marginal vein of rabbit, resulting in improved detection of the liver lesions.
Chapter 3
In vitro and in vivo test of PVP-coated iron oxide nanoparticles for liver-specific MRI contrast agent
Some in vitro and in vivotests were performed with iron oxide nanoparticles coated with polyvinylpyrrolidone (PVP). The characteristics of synthesized PVP-coated iron oxide nanoparticles were confirmed by X-ray diffraction (XRD), transmittance electron microscopy (TEM), electrophoretic light scattering (ELS), infrared spectroscopy (FTIR) and X-ray photoelectron spectroscopy (XPS), and superconducting quantum interface device (SQUID). The MR images of the nanoparticles in water were investigated using a 3.0 T clinical MR imager. T2-weighted image ofthe rabbit liver for the in vivo test was obtained using 3.0T MR imager after administration of the nanoparticles into the marginal vein. After the harvest of rabbit liver, light and transmission electron microscopy study was performed to confirm of the nanoparticles phagocytosed by Kupffer cell. The cell was evaluated using transmittance electron microscope.
Chapter 4
Diethylenetriaminepentaacetic acid-gadolinium (DTPA-Gd) conjugated polysuccinimide derivatives as magnetic resonance imaging (MRI) contrast agent
Biocompatible polysuccinimide (PSI) derivatives conjugated with diethylenetriaminepentaacetic acid gadolinium (DTPA-Gd) were prepared asmagnetic resonance imaging (MRI) contrast agent. In this study, we synthesized PSI including methoxy-poly(ethylene glycol) (mPEG) as hydrophilic ligand, hexadecylamine as hydrophobic ligand, and DTPA-Gd as contrast agent. PSI was synthesized by polycondensation polymerization of aspartic acid. All the synthesized materials were characterized by proton nuclear magnetic resonance (1H-NMR). Critical micellization concentrations were determined using fluorescent probes (pyrene). Micelle size and shape were measured by electro light scattering (ELS) and atomic force microscope (AFM). The formed micelle size was ranged from 100 to 300 nm. The T1- weighted MR images of phantom prepared with PSI-mPEG-C16-(DTPA-Gd) were obtained in a 3.0T clinical MR imager and the results showed the great potentiality as MRI contrast agent.
Chapter 5
Biocompatible poly-[N-(2-hydroxyethyl)-DL-aspartamide]-lysine-(DOTA -gadolinium) complex for magnetic resonance imaging (MRI) contrast agent
A novel biocompatible Poly(N-2-hydroxyethyl-DL-aspartamide)-Lysine -(1,4,7,10-tetraazacyclododecan-1,4,7,10-tetraacetic acid-Gd) (PHEA-Lysine- (DOTA-Gd)) has been prepared by the conjugation of DOTA-Gd via Lysine bridge on the backbone chains of poly(α,β-poly(N-2-hydroxyethyl)-D.L.- aspartamide) (PHEA). The compound was characterized by nuclear magnetic resonance spectrometer (1H-NMR), Fourier Transformed Infrared (FTIR), elemental analyzer (EA), and energy dispersive x-ray spectrometer (EDS). The size of macromolecule was measured by electro-photometer light scattering (ELS), and atomic force microscope (AFM). The average diameter of prepared macromolecule was 180 nm. Also, T1-weighted MR images of prepared samples and commercially available Omniscan?? were acquired. In vivo contrast enhancement in magnetic resonance imaging (MRI) was observed with the administration of PHEA-Lysine-(DOTA-Gd) through the marginal vein of rabbit, resulting in improved detection of the liver lesions.
분석정보
서지정보 내보내기(Export)
닫기소장기관 정보
닫기권호소장정보
닫기오류접수
닫기오류 접수 확인
닫기음성서비스 신청
닫기음성서비스 신청 확인
닫기이용약관
닫기학술연구정보서비스 이용약관 (2017년 1월 1일 ~ 현재 적용)
학술연구정보서비스(이하 RISS)는 정보주체의 자유와 권리 보호를 위해 「개인정보 보호법」 및 관계 법령이 정한 바를 준수하여, 적법하게 개인정보를 처리하고 안전하게 관리하고 있습니다. 이에 「개인정보 보호법」 제30조에 따라 정보주체에게 개인정보 처리에 관한 절차 및 기준을 안내하고, 이와 관련한 고충을 신속하고 원활하게 처리할 수 있도록 하기 위하여 다음과 같이 개인정보 처리방침을 수립·공개합니다.
주요 개인정보 처리 표시(라벨링)
목 차
3년
또는 회원탈퇴시까지5년
(「전자상거래 등에서의 소비자보호에 관한3년
(「전자상거래 등에서의 소비자보호에 관한2년
이상(개인정보보호위원회 : 개인정보의 안전성 확보조치 기준)개인정보파일의 명칭 | 운영근거 / 처리목적 | 개인정보파일에 기록되는 개인정보의 항목 | 보유기간 | |
---|---|---|---|---|
학술연구정보서비스 이용자 가입정보 파일 | 한국교육학술정보원법 | 필수 | ID, 비밀번호, 성명, 생년월일, 신분(직업구분), 이메일, 소속분야, 웹진메일 수신동의 여부 | 3년 또는 탈퇴시 |
선택 | 소속기관명, 소속도서관명, 학과/부서명, 학번/직원번호, 휴대전화, 주소 |
구분 | 담당자 | 연락처 |
---|---|---|
KERIS 개인정보 보호책임자 | 정보보호본부 김태우 | - 이메일 : lsy@keris.or.kr - 전화번호 : 053-714-0439 - 팩스번호 : 053-714-0195 |
KERIS 개인정보 보호담당자 | 개인정보보호부 이상엽 | |
RISS 개인정보 보호책임자 | 대학학술본부 장금연 | - 이메일 : giltizen@keris.or.kr - 전화번호 : 053-714-0149 - 팩스번호 : 053-714-0194 |
RISS 개인정보 보호담당자 | 학술진흥부 길원진 |
자동로그아웃 안내
닫기인증오류 안내
닫기귀하께서는 휴면계정 전환 후 1년동안 회원정보 수집 및 이용에 대한
재동의를 하지 않으신 관계로 개인정보가 삭제되었습니다.
(참조 : RISS 이용약관 및 개인정보처리방침)
신규회원으로 가입하여 이용 부탁 드리며, 추가 문의는 고객센터로 연락 바랍니다.
- 기존 아이디 재사용 불가
휴면계정 안내
RISS는 [표준개인정보 보호지침]에 따라 2년을 주기로 개인정보 수집·이용에 관하여 (재)동의를 받고 있으며, (재)동의를 하지 않을 경우, 휴면계정으로 전환됩니다.
(※ 휴면계정은 원문이용 및 복사/대출 서비스를 이용할 수 없습니다.)
휴면계정으로 전환된 후 1년간 회원정보 수집·이용에 대한 재동의를 하지 않을 경우, RISS에서 자동탈퇴 및 개인정보가 삭제처리 됩니다.
고객센터 1599-3122
ARS번호+1번(회원가입 및 정보수정)